Skip to content
May 28, 2025

Aktis Oncology Initiates Phase 1b Clinical Trial Of Its Nectin-4- Targeting Radiopharmaceutical Product Candidate, Aky-1189, Across Multiple Tumor Types

You are about to leave MPM BioImpact's website. MPM BioImpact is not responsible for the content on other companies' websites.

Cancel Continue